{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:17Z","timestamp":1791685337721,"version":"4.3.4"},"reference-count":60,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Huizhou Science and Technology Innovation Team Project","award":["2023EQ050012"],"award-info":[{"award-number":["2023EQ050012"]}]},{"name":"Huizhou Outstanding Young Scientific and Technological Talents Program","award":["2025EQ050018"],"award-info":[{"award-number":["2025EQ050018"]}]},{"name":"Guangzhou Medical University Research Ability Enhancement Project","award":["2024SRP215"],"award-info":[{"award-number":["2024SRP215"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023A1515140145"],"award-info":[{"award-number":["2023A1515140145"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,24]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leptomeningeal metastasis (LM) is a fatal complication of advanced cancer with limited therapeutic options and poor prognosis. Immune checkpoint inhibitors (ICIs) have shown promise in systemic disease, but intrathecal ICIs efficacy and immunological impact in LM remain unclear. Cerebrospinal fluid (CSF) proteomics may provide a unique window into the CNS immune microenvironment and enable response prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 62 patients with LM who received intrathecal pemetrexed (InPe) with or without ICIs (InPe+programmed cell death protein-1 (PD-1), InPe+PD-1+cytotoxic T-lymphocyte associated protein 4 (CTLA-4), InPe+PD-1+vascular endothelial growth factor (VEGF)). Matched CSF (pretreatment and post-treatment) and pretreatment serum samples were collected for high-content proteomic profiling using the Olink platform. Differential expression, pathway enrichment, and machine learning-based modeling were applied to identify treatment-induced changes and predictive biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nearly half of the patients achieved clinical response. Post-treatment CSF showed enrichment of cytokine and chemokine signaling pathways, with a marked decrease in EGF. Adding PD-1 inhibitor restored immune cell function and upregulated interferon-\u03b3. Compared with serum, CSF proteomic profiles provided superior predictive performance (area under the curve (AUC) 0.884 vs 0.780). A five-protein CSF signature (ADGRG1, CD28, CCL23, DCN, IL-15) achieved robust prediction (AUC 0.968 in InPe+PD-1 training cohort, 0.917 in InPe+PD-1+CTLA-4 validation cohort, and 1 in InPe+PD-1 subsequent validation cohort). ADGRG1 was significantly higher in non-responders at baseline (p=0.031) and decreased after treatment, and specific enrichment in dura-derived LM-associated macrophages, suggesting a macrophage-derived source and potential role in LM progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first high-content proteomic atlas of intrathecal ICI therapy in LM, identifies intrathecal ICI therapy-specific immune remodeling in LM, and establishes a CSF-based predictive model with high accuracy. ADGRG1 represents a promising biomarker of treatment responsiveness and a potential mechanistic link between macrophage biology and LM progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013588","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:35:23Z","timestamp":1771508123000},"page":"e013588","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct06462222","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06809530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06809517","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06762080","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06462222","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06809530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06809517","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06762080","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9416-7647","authenticated-orcid":false,"given":"Lishi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozi","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Center, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease Key Laboratory of Biological Targeting Diagnosis Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-7758","authenticated-orcid":false,"given":"Zhenyu","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026021905351477000_14.2.e013588.1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae103"},{"key":"2026021905351477000_14.2.e013588.2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002473","article-title":"Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers","volume":"9","author":"Naidoo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026021905351477000_14.2.e013588.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.12.004"},{"key":"2026021905351477000_14.2.e013588.4","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","article-title":"Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial","volume":"31","author":"Preusser","year":"2025","journal-title":"Nat Med"},{"key":"2026021905351477000_14.2.e013588.5","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1953.0049"},{"key":"2026021905351477000_14.2.e013588.6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41586-025-09012-z","article-title":"Interferon-\u03b3 orchestrates leptomeningeal anti-tumour response","volume":"643","author":"Remsik","year":"2025","journal-title":"Nature New Biol"},{"key":"2026021905351477000_14.2.e013588.7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/s43018-024-00858-2","article-title":"Dura immunity configures leptomeningeal metastasis immunosuppression for cerebrospinal fluid barrier invasion","volume":"5","author":"Zhao","year":"2024","journal-title":"Nat Cancer"},{"key":"2026021905351477000_14.2.e013588.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3153"},{"key":"2026021905351477000_14.2.e013588.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2026021905351477000_14.2.e013588.10","doi-asserted-by":"crossref","first-page":"1567324","DOI":"10.3389\/fimmu.2025.1567324","article-title":"Intrathecal administration of PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from breast cancer: a case report","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"2026021905351477000_14.2.e013588.11","doi-asserted-by":"crossref","first-page":"108586","DOI":"10.1016\/j.lungcan.2025.108586","article-title":"Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma","volume":"204","author":"Ruan","year":"2025","journal-title":"Lung Cancer (Auckl)"},{"key":"2026021905351477000_14.2.e013588.12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat Med"},{"key":"2026021905351477000_14.2.e013588.13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11060-024-04843-8","article-title":"Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence","volume":"170","author":"Zhen","year":"2024","journal-title":"J Neurooncol"},{"key":"2026021905351477000_14.2.e013588.14","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/neuonc\/noaf025","article-title":"Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study)","volume":"27","author":"Fan","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026021905351477000_14.2.e013588.15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-21-3017","article-title":"Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis","volume":"28","author":"Fitzpatrick","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026021905351477000_14.2.e013588.16","doi-asserted-by":"crossref","first-page":"108593","DOI":"10.1016\/j.lungcan.2025.108593","article-title":"Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors","volume":"205","author":"Xie","year":"2025","journal-title":"Lung Cancer (Auckl)"},{"key":"2026021905351477000_14.2.e013588.17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00387","article-title":"Identification of Cerebrospinal Fluid MicroRNAs Associated With Leptomeningeal Metastasis From Lung Adenocarcinoma","volume":"10","author":"Pan","year":"2020","journal-title":"Front Oncol"},{"key":"2026021905351477000_14.2.e013588.18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/02648725.2023.2191069","article-title":"Cerebrospinal fluid exosomal microRNAs as biomarkers for diagnosing or monitoring the progression of non-small cell lung cancer with leptomeningeal metastases","volume":"40","author":"Li","year":"2024","journal-title":"Biotechnol Genet Eng Rev"},{"key":"2026021905351477000_14.2.e013588.19","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s00432-022-04053-7","article-title":"The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026021905351477000_14.2.e013588.20","doi-asserted-by":"crossref","first-page":"1339914","DOI":"10.3389\/fimmu.2024.1339914","article-title":"Diagnostic value of cerebrospinal fluid human epididymis protein 4 for leptomeningeal metastasis in lung adenocarcinoma","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"2026021905351477000_14.2.e013588.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006616","article-title":"Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer","volume":"12","author":"Gao","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026021905351477000_14.2.e013588.22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116304","article-title":"Serum Proteomics in Patients with Head and Neck Cancer: Peripheral Blood Immune Response to Treatment","volume":"23","author":"Astradsson","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026021905351477000_14.2.e013588.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.012"},{"key":"2026021905351477000_14.2.e013588.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026021905351477000_14.2.e013588.25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1311"},{"key":"2026021905351477000_14.2.e013588.26","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(94)90159-7"},{"key":"2026021905351477000_14.2.e013588.27","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1984.04050210082020"},{"key":"2026021905351477000_14.2.e013588.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42682-9","article-title":"Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis","volume":"14","author":"\u00c5kesson","year":"2023","journal-title":"Nat Commun"},{"key":"2026021905351477000_14.2.e013588.29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009345","article-title":"Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"12","author":"Ju","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026021905351477000_14.2.e013588.30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","article-title":"Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma","volume":"164","author":"Zhou","year":"2023","journal-title":"Gastroenterology"},{"key":"2026021905351477000_14.2.e013588.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03215-4","article-title":"Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy","volume":"43","author":"Gorgulho","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"2026021905351477000_14.2.e013588.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"2026021905351477000_14.2.e013588.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.007"},{"key":"2026021905351477000_14.2.e013588.34","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"2026021905351477000_14.2.e013588.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026021905351477000_14.2.e013588.36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003731","article-title":"Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer","volume":"10","author":"Maeda","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026021905351477000_14.2.e013588.37","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108"},{"key":"2026021905351477000_14.2.e013588.38","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1080\/15548627.2021.2008692","article-title":"DCN released from ferroptotic cells ignites AGER-dependent immune responses","volume":"18","author":"Liu","year":"2022","journal-title":"Autophagy"},{"key":"2026021905351477000_14.2.e013588.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101231","article-title":"Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics","volume":"4","author":"Qin","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026021905351477000_14.2.e013588.40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7150\/jca.17192","article-title":"Identifying DCN and HSPD1 as Potential Biomarkers in Colon Cancer Using 2D-LC-MS\/MS Combined with iTRAQ Technology","volume":"8","author":"Li","year":"2017","journal-title":"J Cancer"},{"key":"2026021905351477000_14.2.e013588.41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature New Biol"},{"key":"2026021905351477000_14.2.e013588.42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41586-023-05872-5","article-title":"Structural mechanisms for regulation of GSDMB pore-forming activity","volume":"616","author":"Zhong","year":"2023","journal-title":"Nature New Biol"},{"key":"2026021905351477000_14.2.e013588.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2008.11.008"},{"key":"2026021905351477000_14.2.e013588.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.06.008"},{"key":"2026021905351477000_14.2.e013588.45","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292"},{"key":"2026021905351477000_14.2.e013588.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.11.008"},{"key":"2026021905351477000_14.2.e013588.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2016.06.001"},{"key":"2026021905351477000_14.2.e013588.48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the Combination Immunotherapy of Cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front Immunol"},{"key":"2026021905351477000_14.2.e013588.49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s43556-025-00291-6","article-title":"Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1\/PD-L1 blockades in NSCLC: a prospective exploratory study","volume":"6","author":"Gao","year":"2025","journal-title":"Mol Biomed"},{"key":"2026021905351477000_14.2.e013588.50","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03781-8","article-title":"Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1\/L1 inhibitor monotherapy","volume":"73","author":"Murata","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026021905351477000_14.2.e013588.51","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.15410","article-title":"Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review","volume":"182","author":"van Westrhenen","year":"2018","journal-title":"Br J Haematol"},{"key":"2026021905351477000_14.2.e013588.52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020449","article-title":"Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma\/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid","volume":"14","author":"Juanes-Velasco","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026021905351477000_14.2.e013588.53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-539726"},{"key":"2026021905351477000_14.2.e013588.54","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7121","article-title":"The adhesion G protein-coupled receptor GPR56 is a cell-autonomous regulator of oligodendrocyte development","volume":"6","author":"Giera","year":"2015","journal-title":"Nat Commun"},{"key":"2026021905351477000_14.2.e013588.55","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1016\/j.neuron.2025.06.020","article-title":"G-protein-coupled receptor ADGRG1 drives a protective microglial state in Alzheimer\u2019s disease through MYC activation","volume":"113","author":"Zhu","year":"2025","journal-title":"Neuron"},{"key":"2026021905351477000_14.2.e013588.56","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123352","article-title":"Role of ADGRG1\/GPR56 in Tumor Progression","volume":"10","author":"Ng","year":"2021","journal-title":"Cells"},{"key":"2026021905351477000_14.2.e013588.57","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-07095-6","article-title":"GPR56 facilitates hepatocellular carcinoma metastasis by promoting the TGF-\u03b2 signaling pathway","volume":"15","author":"Luo","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026021905351477000_14.2.e013588.58","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0436"},{"key":"2026021905351477000_14.2.e013588.59","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396"},{"key":"2026021905351477000_14.2.e013588.60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3208"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:35:29Z","timestamp":1771508129000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,19]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013588"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013588","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}